Position in REPL
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$29,789
New position
Shares Held
2,691
first reported quarter
Ownership
0.003%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#19
of 39 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026TFC Financial Management, Inc. holds $462,229 across 45 Biotechnology names. REPL ranks #5 (6.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
316 | $156,966 | |
| 2 | REGN |
Regeneron Pharmaceuticals, Inc.
|
89 | $55,495 | |
| 3 | TNGX |
Tango Therapeutics, Inc.
|
1,650 | $51,579 | |
| 4 | CRSP |
CRISPR Therapeutics AG
|
620 | $33,814 | |
| 5 | REPL |
Replimune Group, Inc.
This page
|
2,691 | $29,789 | |
| 6 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
72 | $21,674 | |
| 7 | MRNA |
Moderna, Inc.
|
264 | $18,487 | |
| 8 | HALO |
Halozyme Therapeutics, Inc.
|
211 | $16,514 |
All Filings in REPL
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $29,789 | 2,691 | Shares | Sole | 2026-07-23 | |
| No filing history on record for this holder in this stock. | ||||||